Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dasatinib in Children and Adolescents With Ph+ Leukemias Resistant or Intolerant to Imatinib
2024-510784-36-00Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- May 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 5
01
Overview
Phase 2, open-label trial of dasatinib in chronic myelogenous leukemia (CML) and acute lymphoblastic leukemia (ALL) (3 cohorts), sponsored by Bristol Myers Squibb. Primary endpoints: Major cytogenetic response rate in Cohort 1 and Complete hematologic response rate in Cohort 2. Started May 2024; status: completed.
02
Drugs
dasatinib
03
Conditions
chronic myelogenous leukemia (CML)acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on 2024-510784-36-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-510784-36-00.